A Research Study to Compare Two Types of Insulin, a New Weekly Insulin, Insulin Icodec and an Available Daily Insulin, Insulin Glargine, Both in Combination With Mealtime Insulin, in People With Type 2 Diabetes Who Use Daily Insulin and Mealtime Insulin (ONWARDS 4)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 582 participants.

Also called NCT04880850

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 582 participants (enrolled count) (from the registry)
Sponsor
  • Novo Nordisk Registry lists this organization as the lead sponsor
Registry
  • NCT NCT04880850
  • EudraCT 2020-000474-16
Main results
  • Switching to once-weekly insulin icodec versus once-daily insulin glargine U100 in individuals with basal-bolus insulin-treated type 2 diabetes (ONWARDS 4): a phase 3a, randomised, open-label, multicentre, treat-to-target, non-inferiority trial Lancet (London, England), 2023-06-10 DOI, PubMed 37156252

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Belgium, India, Italy, Japan, Mexico, Netherlands, Romania, Russia (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04880850. Randomized; no masking; primary purpose treatment. Start 2021-05-14 (actual); primary completion 2022-06-16 (actual). Results posted on 2025-07-02.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Research Study to Compare Two Types of Insulin, a New Weekly Insulin, Insulin Icodec and an Available Daily Insulin, Insulin Glargine, Both in Combination With Mealtime Insulin, in People With Type 2 Diabetes Who Use Daily Insulin and Mealtime Insulin (ONWARDS 4)
Acronym
ONWARDS 4
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
Insulin icodec
Intervention (Drug)
Insulin glargine
Intervention (Drug)
Insulin aspart
Lead sponsor
Novo Nordisk A/S (class: industry)

Record details

Record id
cardio:ct-nct04880850
Content hash
f6293ecefa3dcbd7111c684053895c600f29aa548a462a469d4b1ec74a6205c3